Abiopharma

🔍 Zugelder Dan (Executive)

Company: Dynatrace, Inc. (DT)

Report Date: 2026-06-05

Detailed Transactions and Holdings:

• Acquired 13,918 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 41,518.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 6,973 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 34,545.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 6,387 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 40,932.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 3,200 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 37,732.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 3,221 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 40,953.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 1,614 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 39,339.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 4,130 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 43,469.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 2,070 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 41,399.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 4,043 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 45,442.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 2,026 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 43,416.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 16,177 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 59,593.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 8,105 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 51,488.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 11,063 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 62,551.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 5,543 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 57,008.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 13,918 shares of Performance Restricted Stock Units (Financial) (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F4, F1
• Sold 6,387 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 25,550.00 | transaction_form_type: 4 | Footnotes: F1, F5, F1
• Sold 3,221 shares of Performance Restricted Stock Units (Financial) (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,883.00 | transaction_form_type: 4 | Footnotes: F1, F6, F1
• Sold 4,130 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 16,520.00 | transaction_form_type: 4 | Footnotes: F1, F7, F1
• Sold 4,043 shares of Performance Restricted Stock Units (rTSR) (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F8, F1
• Sold 16,177 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 32,843.00 | transaction_form_type: 4 | Footnotes: F1, F9, F1
• Sold 11,063 shares of Performance Restricted Stock Units (Financial) (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 22,459.00 | transaction_form_type: 4 | Footnotes: F1, F10, F1
• Acquired 61,034 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 61,034.00 | transaction_form_type: 4 | Footnotes: F1, F11, F1

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units do not expire. They either vest or are cancelled prior to the vesting date.
• F2: Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations upon the vesting of restricted stock units.
• F3: The number of securities reported reflects the acquisition on June 5, 2026 of 558 shares of Common Stock pursuant to the Issuer's Employee Stock Purchase Plan ("ESPP") for the ESPP offering period of December 6, 2025 through June 5, 2026.
• F4: Represents the vesting of restricted stock units based on financial performance ("Financial PSUs") granted on July 15, 2023 under the Issuer's 2019 Equity Incentive Plan, as amended (the "Plan"). 33% of the Financial PSUs granted vested on June 5, 2024 and the balance of the Financial PSUs vested in equal quarterly installments thereafter until fully vested on June 5, 2026.
• F5: Represents the vesting of time-based restricted stock units ("RSUs") granted on July 15, 2023 under the Plan. 12.5% of the RSUs granted vested on December 5, 2023 and the balance of the RSUs vest in equal quarterly installments thereafter until fully vested on June 5, 2027, subject to the Reporting Person's continued employment on the applicable vesting dates.
• F6: Represents the vesting of Financial PSUs granted on June 5, 2024 under the Plan. 33% of the Financial PSUs granted vested on June 5, 2025 and the balance of the Financial PSUs vest in equal quarterly installments thereafter until fully vested on June 5, 2027, subject to the Reporting Person's continued employment on the applicable vesting dates.
• F7: Represents the vesting of RSUs granted on June 5, 2024 under the Plan. 33% of the RSUs granted vested on June 5, 2025 and the balance of the RSUs vest in equal quarterly installments thereafter until fully vested on June 5, 2027, subject to the Reporting Person's continued employment on the applicable vesting dates.
• F8: Represents the vesting of restricted stock units based on relative total stockholder return ("rTSR PSUs") granted on June 5, 2024 under the Plan. These rTSR PSUs were earned following certification by the Compensation Committee of the Board of Directors of the Issuer (the "Compensation Committee") of certain performance conditions related to relative total stockholder return for the two year performance period that started on April 1, 2024 and ended on March 31, 2026. All of these rTSR PSUs vested on June 5, 2026.
• F9: Represents the vesting of RSUs granted on June 5, 2025 under the Plan. 33% of the RSUs vested on June 5, 2026 and the balance of the RSUs vest in equal quarterly installments thereafter until fully vested on June 5, 2028, subject to the Reporting Person's continued employment on the applicable vesting dates.
• F10: Represents the vesting of Financial PSUs granted on June 5, 2025 under the Plan and earned following certification by the Compensation Committee of certain financial performance results for the Issuer's fiscal year 2026 that started on April 1, 2025 and ended on March 31, 2026. 33% of the Financial PSUs vested on June 5, 2026, and the balance of the Financial PSUs vest in equal quarterly installments thereafter until fully vested on June 5, 2028, subject to the Reporting Person's continued employment on the applicable vesting dates.
• F11: Represents the grant of RSUs under the Plan. 33% of these RSUs will vest on June 5, 2027 and the balance of the RSUs will vest in equal quarterly installments thereafter until fully vested on June 5, 2029, subject to the Reporting Person's continued employment on the applicable vesting dates.